Evidence-based Complementary and Alternative Medicine Journal Impact Factor & Information

Publisher: Hindawi Publishing Corporation

Journal description

Evidence-based Complementary and Alternative Medicine (eCAM) is an international, peer-reviewed journal that seeks to understand the sources and to encourage rigorous research in this new, yet ancient world of complementary and alternative medicine. The Journal seeks to apply scientific rigor to the study of complementary and alternative medicine (CAM) modalities, particularly traditional Asian healing systems. eCAM emphasizes health outcome, while documenting biological mechanisms of action. The journal is devoted to the advancement of science in the field of basic research, clinical studies, methodology or scientific theory in diverse areas of Biomedical Sciences.

Current impact factor: 1.88

Impact Factor Rankings

2015 Impact Factor Available summer 2015
2013 / 2014 Impact Factor 2.175
2012 Impact Factor 1.722
2011 Impact Factor 4.774
2010 Impact Factor 2.964
2009 Impact Factor 2.064
2008 Impact Factor 1.954
2007 Impact Factor 2.535

Impact factor over time

Impact factor

Additional details

5-year impact 2.14
Cited half-life 2.30
Immediacy index 0.41
Eigenfactor 0.01
Article influence 0.37
Website Evidence-based Complementary and Alternative Medicine website
Other titles Evidence-based complementary and alternative medicine (Online), ECAM
ISSN 1741-427X
OCLC 55647292
Material type Document, Periodical, Internet resource
Document type Internet Resource, Computer File, Journal / Magazine / Newspaper

Publisher details

Hindawi Publishing Corporation

  • Pre-print
    • Author can archive a pre-print version
  • Post-print
    • Author can archive a post-print version
  • Conditions
    • Publisher's version/PDF may be used
    • Creative Commons Attribution License
    • Eligible UK authors may deposit in OpenDepot
    • All titles are open access journals
  • Classification
    ​ green

Publications in this journal

  • Evidence-based Complementary and Alternative Medicine 08/2015; DOI:10.1177/2156587215599470
  • Evidence-based Complementary and Alternative Medicine 08/2015;
  • [Show abstract] [Hide abstract]
    ABSTRACT: Rhubarb root and rhizome (RRR) has been clinically used for stroke at least 2000 years and is still used in modern times in both China and elsewhere worldwide. The objective of present study was to evaluate the efficacy of active compounds of RRR (ACRRR) for experimental ischemic stroke. Studies of ACRRR in animal models of ischemic stroke were identified from 5 databases until April 2014. Study quality for each included article was evaluated according to the CAMARADES 10-item checklist. Outcome measures were neurological deficit score and infarct size. All the data were analyzed using RevMan 5.1 software. As a result, 20 studies were identified describing procedures involving 577 animals. The quality score of studies range from 2 to 6, and the median was 3.4. Six studies showed significant effects of ACRRR for improving infarct size compared with model group (P < 0.01). Six studies indicated significant effects of ACRRR for improving the neurological deficit scores according to Zea longa criterion or Eight-point criterion (P < 0.01). In conclusions, these findings demonstrated a possible efficacy of ACRRR that have potential neuroprotective effect for experimental ischemic stroke. However, these apparently positive findings should be interpreted with cautions because of the methodological flaws.
    Evidence-based Complementary and Alternative Medicine 07/2015; 2015(210546):210546.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Trichophyton rubrum is the most common causative agent of dermatomycoses worldwide, causing infection in the stratum corneum, nails, and hair. Despite the high prevalence of these infections, little is known about the molecular mechanisms involved in the fungal-host interaction, particularly during antifungal treatment. The aim of this work was to evaluate the gene expression of T. rubrum cocultured with keratinocytes and treated with the flavonoid trans-chalcone and the glycoalkaloid α-solanine. Both substances showed a marked antifungal activity against T. rubrum strain CBS (MIC = 1.15 and 17.8 µg/mL, resp.). Cytotoxicity assay against HaCaT cells produced IC50 values of 44.18 to trans-chalcone and 61.60 µM to α-solanine. The interaction of keratinocytes with T. rubrum conidia upregulated the expression of genes involved in the glyoxylate cycle, ergosterol synthesis, and genes encoding proteases but downregulated the ABC transporter TruMDR2 gene. However, both antifungals downregulated the ERG1 and ERG11, metalloprotease 4, serine proteinase, and TruMDR2 genes. Furthermore, the trans-chalcone downregulated the genes involved in the glyoxylate pathway, isocitrate lyase, and citrate synthase. Considering the urgent need for more efficient and safer antifungals, these results contribute to a better understanding of fungal-host interactions and to the discovery of new antifungal targets.
    Evidence-based Complementary and Alternative Medicine 07/2015; 2015(2). DOI:10.1155/2015/180535